als, Novavax
Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales
based on current trends. The company also cut its sales projection when it reported second-quarter earnings in August. Novavax's COVID vaccine brought in sales of $38.21 million for the third quarter, ahead of analysts' average expectations of $29 million ...
Novavax, Inc., based in Gaithersburg, Maryland, is a global biotechnology company focused on developing and commercializing innovative protein-based vaccines to combat serious infectious ...
Graeme Sloan / Bloomberg via Getty Images Novavax said the Food and Drug Administration allowed it to continue testing a combination COVID-19-flu and standalone flu vaccine that had been put on ...
Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold. The Gaithersburg, Md., vaccine developer said Monday that the U.S ...
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Investing.com -- The U.S. Food and Drug Administration (FDA) has lifted its hold on a late-stage trial for Novavax’s COVID-influenza combination and standalone flu vaccines, the company reported ...
Based on this, the drug regulator has cleared the company to begin enrollment in the vaccines' planned Phase 3 trial. Novavax (NVAX) will be working with the clinical trial investigators and ...
Novavax has inked ... entered into a COVID vaccine supply deal in October 2020. The U.K. originally agreed to purchase 60 million doses of the company’s protein-based adjuvanted shot NVX-CoV2373 ...
Novavax can move forward with a trial for its combined Covid-19 and influenza vaccine after regulators lifted a clinical hold. The Gaithersburg, Md., vaccine developer said Monday that the U.S ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback